**Supplementary tables**

**Table S1. Responder rates based on 30% and 50% improvement at the end of the double-blind efficacy phase in the average pain intensity score (Baseline observation carried forward), Intent-to-treat analysis set**

| **Responder rates at week 12** | **PHN** | | | | **PTN** | |
| --- | --- | --- | --- | --- | --- | --- |
| **Placebo**  **n (%)** | **Fulranumab**  **1mgQ4wk**  **n (%)** | **Fulranumab**  **3mgQ4wk**  **n (%)** | **Fulranumab**  **10mgQ4wk**  **n (%)** | **Placebo**  **n (%)** | **Fulranumab**  **10mgQ4wk**  **n (%)** |
| **Pain assessment ≥30% improved** |  |  |  |  |  |  |
| Yes | 5 (25.0) | 5 (38.5) | 2 (15.4) | 4 (21.1) | 6 (27.3) | 5 (21.7) |
| No | 15 (75.0) | 8 (61.5) | 11 (84.6) | 15 (78.9) | 16 (72.7) | 18 (78.3) |
| Total | 20 | 13 | 13 | 19 | 22 | 23 |
| P-value (minus placebo)a |  | 0.42 | 0.52 | 0.78 |  | 0.72 |
| **Pain assessment ≥50% improved** |  |  |  |  |  |  |
| Yes | 3 (15.0) | 2 (15.4) | 2 (15.4) | 3 (15.8) | 5 (22.7) | 2 (8.7) |
| No | 17 (85.0) | 11 (84.6) | 11 (84.6) | 16 (84.2) | 17 (77.3) | 21 (91.3) |
| Total | 20 | 13 | 13 | 19 | 22 | 23 |
| P-value (minus placebo)a |  | 0.97 | 0.97 | 0.93 |  | 0.23 |

aPairwise comparison: Generalized Cochran-Mantel-Haenszel test for general association controlling for strata2. strata2, baseline current pain medication

n, number of patients in each group; PHN, postherpetic neuralgia; PTN, posttraumatic neuralgia